This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heartfailure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with Preserved Ejection Fraction (HFpEF).
Background and aims The independent role of body fat distribution and fat-free mass in heartfailure (HF) risk is unclear. Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 years, 44% male) from the UK Biobank. to 1.33).
Bayers FINEARTS-HF study revealed that finerenone could be poised to become the next big heartfailure treatment at ESC 2024, and a new series of JACC sub-studies just further strengthened its case. Finerenone (Bayers Kerendia) got its start with CKD, and is the first mineralocorticoid receptor antagonist to be used for HF.
The interaction between body mass index (BMI) and NT-proBNP with respect to heartfailure (HF) risk remains incompletely defined. Hospitalization for heartfailure (HHF) was examined across strata of baseline BMI and NT-proBNP. pg/mL lower NT-proBNP per 1 kg/m 2 higher BMI; p<0.001).
The triglyceride glucose (TyG) index, TyG-body mass index (TyG-BMI), and triglyceride-density lipoprotein cholesterol ratio (TG/HDL-C) are substitute indicators for insulin resistance (IR). This study aimed to.
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heartfailure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Circulation, Ahead of Print.
The triglyceride glucose-body mass index (TyG-BMI) is recognized as a reliable surrogate for evaluating insulin resistance and an effective predictor of cardiovascular disease. However, the link between TyG-BM.
Metabolic dysfunction and incident heartfailure. Aims The extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heartfailure (HF) incidence and subtypes, remains unclear. Methods and results We included 4069 Jackson Heart Study participants (mean age 54.4years, 63.8%
What is the incremental benefit in patients with heartfailure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
Background High pulse pressure (PP) and aortic root diameter (AoD) are hallmarks of arterial stiffness or vascular aging and they are considered as risk factors for age-related cardiovascular disease, including heartfailure (HF). However, the relationship between PP and AoD in patients with heartfailure (HF) is uncertain.
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heartfailure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%
Hypertensive disorders of pregnancy as a risk factor for heartfailure. BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HELLP, haemolysis, elevated liver enzymes, low platelet count.
Notably, MAG showed superior survival for patients with a BMI less than 40, whereas patients with a BMI of 40 or higher had superior survival with SAG. Survival outcomes were equivalent between MAG and SAG for patients aged 80 years or older, and those with severe heartfailure , renal failure, peripheral vascular disease, or obesity.
Background: Patients with heartfailure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heartfailure. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, points (95%CI, 3.3,
Aims Patients experiencing ischaemic heartfailure with reduced ejection fraction (HFrEF) represent a diverse group. Association between clusters and the composite of (i) heartfailure hospitalization or all-cause death, (ii) cardiovascular (CV) hospitalization or all-cause death, and (iii) major adverse CV events was assessed.
In a recent study published in Circulation: HeartFailure , researchers analyzed a large group of individuals with various cardiopulmonary diseases who had undergone right heart catheterization. year follow-up, those with right ventricular dysfunction faced an increased risk of mortality and heartfailure hospitalization.
Association between body mass index (BMI) and clinical outcomes in PARADISE-MI. ( A ) Histogram for BMI (kg/m 2 ), ( B ) adverse events for BMI subgroups, and spline model curves for ( C ) the primary composite outcome and ( D ) cardiovascular (CV) death by BMI subgroups. 100 patient-years for BMI 40kg/m 2 ).
According to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association , heart disease has been the leading cause of death in the U.S. s first Allia IGS Pulse system at Heart Hospital of New Mexico,” said Brian Miller , chief executive officer of HHNM*.
Among participants with baseline body mass index (BMI) above 30 kg/m2, 70.4% Research shows that a 10 point reduction in systolic blood pressure helps lower the risk of coronary heart disease (17%), stroke (27%), heartfailure (28%), and all-cause mortality (13%).
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] to 25 kg/m2) and underweight (BMI less than 18.5 kg/m2) or severe obesity (BMI greater than 40 kg/m2).
Background:Patients with heartfailure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.
The H2FPEF score and probability were developed to assist in heartfailure with preserved ejection fraction (HFpEF) diagnosis. Results:Overall, 140 participants were identified (age: 56±16 years; BMI: 30.04±8.04 2022 were included. Significant predictors of outcomes were identified using Cox logistic regression analysis.
Propensity score-matched analysis (PSM) (1:1) was performed on age, gender, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, LDL level, left ventricular ejection fraction and various drugs including beta blockers, ACEi and ARBi. The mean age of patients was comparable between both groups (59.8
Socioeconomic status (SES) is a well-validated risk factor for poor outcomes among patients with heartfailure, but its influence on adverse events in patients post-LVAD is poorly understood and may be overestimated. Hispanic ethnicity (17% v 7%, p=0.016) and higher pre-implant BMI (mean 27.5
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heartfailure with preserved ejection fraction. Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity.
Share Cardiovascular Disease Those in the ‘Ideal’ category were 55% less likely to develop diseases of the circulatory system, including: Heart Disease Stroke HeartFailure Atrial Fibrillation For each 10-point increment in lifestyle score, there was a proportionate 20% reduction in these conditions combined.
Of course, these benefits can also extend to individuals with a BMI in the normal range. For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. It’s never too late to start — but the earlier you start the better.
Of course, these benefits can also extend to individuals with a BMI in the normal range. For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. It’s never too late to start — but the earlier you start the better.
Prognostic value of several alternative anthropometric measures in patients with non-ischaemic heartfailure with reduced ejection fraction. The lower part of the figure shows the risk of mortality according to continuous body mass index (BMI) ( left panel ) and waist-to-height ratio (WHtR) ( right panel ).
ObjectiveTo explore the impact of type 2 diabetes mellitus (T2DM) on exercise tolerance and fat oxidation capacity in patients with heartfailure (HF).MethodsWe MethodsWe retrospectively analyzed 108 Chinese patients with HF who were divided into a diabetic group (T2DM group, n=47) and a non-diabetic group (non-T2DM group, n=61).
Results were adjusted to age, sex, body mass index (BMI), and comorbidities.Results:Mean age 66 years (SD 12.019). All patients underwent respiratory polygraphy and esophageal manometry during sleep. Observation time 2003-2024.AHI, Initial proBNP were also analyzed. Cox proportional hazard models were used to analyze the risk.
Objective While greater body mass index (BMI) is associated with increased risk of developing atrial fibrillation (AF), the impact of BMI on outcomes in newly diagnosed AF is unclear. The study population comprised 40 482 participants: 703 underweight (BMI <18.5 kg/m 2 ), 13 095 normal (BMI=18.5–24.9
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heartfailure that has had few therapeutic options. It also lowered their systolic blood pressure and waist circumference.
A multivariate logistic regression model was used to assess for statistically significant differences after controlling for potentially confounding variables including age, sex, BMI, AF, prior MI, COPD, DM, HTN, serum creatinine, and NYHA functional class.Results:A total of 320 patients were included in this analysis, with 230 on BB (72%).
Abstract Aims Understanding the global burden of disease attributable to high body mass index (BMI) is essential for informing public health strategies and interventions to mitigate the impact of obesity-related conditions. Globally in 2021, the deaths and DALYs attributable to high BMI have risen 2.54-fold fold and 2.68-fold
Studies have shown that an increased left ventricular end-diastolic diameter (LVEDD) is associated with worse outcomes in various cardiovascular conditions, including heartfailure, and coronary artery disease (CAD). The restrictive cubic spline in Figure 2 showed that LVEDD greater than 60 mm increased the risk of MACEs.
AP, atrial pressure; AUC, area under the curve; BMI, body mass index; CI, confidence interval; CPA, cardiopulmonary arrest; LDH, lactate dehydrogenase; J-PVAD, Japanese registry for Percutaneous Ventricular Assist Device; VA-ECMO, veno-arterial extracorporeal membrane oxygenation. Risk prediction for cardiogenic shock patients with Impella.
CVD included stroke, congestive heartfailure, coronary heart disease, and angina. Compared with participants without asthma, the prevalence of stroke in those with asthma was increased by 1.607 times; the prevalence of congestive heartfailure was increased by 1.911 times.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content